June and July delivered a busy stretch of leadership moves across pharma and biotech. From major R&D appointments at large drugmakers to a wave of CEO, CMO, and commercial hires across emerging ...
There’s a personalisation crisis in today’s marketing. Nearly 99% of marketers believe personalisation helps strengthen ...
Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impinging patient access to new therapies. That is the finding of a survey by Swiss ...
ADC Therapeutics' chief executive, Ameet Mallik. ADC Therapeutics' chances of upgrading its accelerated approval for diffuse large B-cell lymphoma therapy Zynlonta to a full approval have taken a ...
Just a few weeks after filing for bankruptcy protection, Sangamo Therapeutics has found buyers for some of its key assets, including a Fabry disease therapy and its genomic medicine platforms. PTC ...
In a first for the consumer health wearables category, Google has introduced a feature on its Pixel Watch and Fitbit Air devices that it says can monitor insulin resistance using passive sensors, ...
Alfasigma's $800 million buyout of Intercept Pharma two years ago is starting to look like a poor bet, as its only approved product, Ocaliva, is pulled off the market in the US and all trials of the ...
US cost-effectiveness watchdog ICER has concluded that AstraZeneca's first-in-class aldosterone synthase inhibitor (ASI) Baxfendy for resistant hypertension does not offer value for money. In a ...
Across the pharmaceutical industry, innovation has always been driven by a fundamental commitment to developing therapies that meaningfully improve patients’ lives. It’s a commitment that carries ...
A therapy room used to deliver the one-off, therapist-assisted treatment. Psychedelic drug developer Definium Therapeutics has reported positive phase 3 results with its LSD-based therapy, DT120, in ...
Indeed, GLP-1 therapies currently bring with them the inconvenience of subcutaneous injections, the difficulty of titration, ...
Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's sales prospects. The US regulator has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results